GenomeWeb just published this article in their latest issue. It highlights our collaboration with Toronto’s Sunnybrook Research Institute to clinically validate our ONETest Rapid product that assays infectious diseases.
It goes on to feature our new Series A funding round. Any monies raised will go to support additional clinical studies to validate our syndromic ONETest products for sepsis and nosocomial acquired infections.
Unfortunately, it’s behind GenomeWeb’s paywall but we’re excited to alert you to this news! Press like this is great for us! Please share the link!
We are pleased to share the news that Fusion Genomics has received a $1 million award to conduct a study evaluating our comprehensive, novel ONETest PathoGenome assay for the detection of pathogens associated with respiratory tract infections (RTIs). Due in great part to limitations associated with current diagnostic tests, RTIs are a leading cause of morbidity, mortality, and hospitalizations globally. Faster identification and diagnosis of pathogens responsible for these infections could help reduce their tremendous burden on patients and hospitals.
We are honored by CQDM’s decision to include the ONETest RTI assay among its prestigious portfolio of funded programs. The prospective clinical study, which we will conduct in partnership with Sunnybrook Research Institute, could help to transform the diagnosis and treatment of RTIs.
For more information, click here to read the news release we distributed this morning, and please don’t hesitate to contact us if you have any questions regarding this exciting new project.